Intendis is a specialized pharmaceutical company focusing on the dermatology. The company provides prescription drug products for the treatment of severe skin diseases and develops locally applicable corticosteroid treatments. The therapeutic areas include eczema/atopic dermatitis, acne/rosacea, hemorrhoids, psoriasis and mycoses. The company also plans to develop anti-infectives, anti-inflammatory agents and virostatics. The lead products of the company includes Advantan® (methylprednisolone aceponate) and Nerisona® (diflucortolone valerate) for treating eczema, Travocort® (isoconazole nitrate/difluocortolone valerate) for treating dermatomycoses, Skinoren® (azelaic acid cream) for treating acne, Finacea® (azelaic acid gel) for treating rosacea and Psorcutan® Beta (calcipotriol/betamethasone dipropionate).